News outlets report on GlaxoSmithKline’s (GSK) plans to test its experimental Ebola vaccine in humans.

Bloomberg News: Glaxo’s Ebola Vaccine to Be Tested for Safety in Humans
“U.S. scientists will begin enrolling patients as soon as next week in clinical safety trials of GlaxoSmithKline Plc (GSK)’s experimental Ebola vaccine as the death toll from the disease rises in West Africa…” (Edney, 8/28).

Reuters: GSK Ebola vaccine fast-tracked into U.S., U.K., and African trials
“An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good…” (Hirschler, 8/28).